Skip to main content

Severe Postpartum Haemorrhage

1
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pharmacosmos
PharmacosmosDenmark - Holbaek
1 program
1
Iron isomaltoside 1000Phase 31 trial
Active Trials
NCT01895205Completed13Est. Aug 2015
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
2 programs
Eptacog alfaN/A1 trial
Eptacog alfaPHASE_41 trial
Active Trials
NCT04444856Completed225Est. Jan 2021
NCT07157423Recruiting64Est. Mar 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Novo NordiskEptacog alfa
PharmacosmosIron isomaltoside 1000
Novo NordiskEptacog alfa

Clinical Trials (3)

Total enrollment: 302 patients across 3 trials

NCT07157423Novo NordiskEptacog alfa

A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India

Start: Aug 2025Est. completion: Mar 202764 patients
Phase 4Recruiting
NCT01895205PharmacosmosIron isomaltoside 1000

Treatment of Women After Severe Postpartum Haemorrhage

Start: Jun 2013Est. completion: Aug 201513 patients
Phase 3Completed
NCT04444856Novo NordiskEptacog alfa

Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of Bern

Start: Jun 2020Est. completion: Jan 2021225 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 302 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.